Envista price to free cash flow NVST

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Oct 23, 2026: 15.3×
6-year median: 19.1×
Against its 6-year history: 31st; percentile: 0 is its lowest day, 100 its highest
6-year range: 8.6× to 62.4×
Peer median: 27.3×

Envista's price to free cash flow is 15.3× as of Oct 23, 2026.

That is below its 6-year median of 19.1×, lower than on 69% of days in the last 6 years.

Over that time it ranged from 8.6× in Apr 2025 to 62.4× in Mar 2023.

The median for 10 medical instruments and supplies stocks of a similar size is 27.3×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	15.3×	13.6×	20.8×
2025	13.8×	8.6×	14.0×
2024	12.1×	9.7×	19.2×
2023	19.0×	17.0×	62.4×
2022	39.0×	19.0×	44.0×
2021	20.2×	14.7×	29.9×
2020	23.7×	18.6×	25.9×

Against its peers

Companies in Medical - Instruments & Supplies nearest Envista's size, closest first, today.

Company	Price to free cash flow
NVSTEnvista	15.3×
ICUIICU Medical	27.3×
BMIBadger Meter	29.2×
WRBYWarby Parker	147×
VNTVontier	12.1×
ATRCAtriCure	56.5×
HAEHaemonetics	18.5×
MMSIMerit Medical Systems	27.4×
UFPTUFP Technologies	n/m
INSPInspire Medical Systems	17.6×
MSAMSA Safety	19.8×
Peer median	27.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Envista

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.